Increased expression of inhibitor of apoptosis proteins, survivin and XIAP, in non-small cell lung carcinoma

  • Authors:
    • Evzen Krepela
    • Petra Dankova
    • Erika Moravcikova
    • Anna Krepelova
    • Jan Prochazka
    • Jan Cermak
    • Jan Schützner
    • Petr Zatloukal
    • Kamila Benkova
  • View Affiliations

  • Published online on: December 1, 2009     https://doi.org/10.3892/ijo_00000464
  • Pages: 1449-1462
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Members of the inhibitor of apoptosis protein (IAP) family, survivin and X-chromosome-linked IAP (XIAP), contribute to apoptosis resistance of cancer cells, and an increase in their expression may elevate the apoptotic threshold of malignant tumours during their growth and progression. In the present study, we investigated the expression status of survivin and its interactants hepatitis B X-interacting protein (HBXIP) and XIAP in non-small cell lung carcinoma (NSCLC) cell lines and NSCLC tumours and matched lungs from surgically treated patients in relation to their clinicopathological data. The expression of survivin, HBXIP and XIAP mRNAs was quantitated by real-time RT-PCR. The expression of survivin and XIAP proteins was analysed by Western blotting and ELISA. Survivin mRNA and protein levels were highly upregulated in NSCLC cells and tissues as compared to the lungs. In fact, the levels of survivin mRNA and protein in the tumours were more than 10-fold higher in 96 (64%) and 72 (82%) of the 150 and 88 examined NSCLC patients, respectively. The expression of survivin mRNA was higher in squamous cell lung carcinomas than in lung adenocarcinomas (LACs; P=0.003) and in less-differentiated tumours than in well-differentiated ones (P=0.007). The level of survivin protein was higher in stage IB and stage II+III tumours (P=0.049 and P=0.044), than in stage IA tumours. The BIRC5 promoter polymorphism at nucleotide -31 did not influence the expression of survivin mRNA and protein in NSCLC cells and tumours. HBXIP mRNA was abundantly expressed in NSCLC cell lines and NSCLC tumours and lungs, while its level was comparable in the tumours and lungs. The expression of XIAP mRNA in NSCLC cell lines and NSCLC tumours and lungs was not significantly different. However, the expression of XIAP protein was higher in NSCLC tumours, particularly in LACs, as compared to the lungs (P=0.017 and P=0.004). In conclusion, the overexpression of survivin in the majority of NSCLCs together with the abundant or upregulated expression of HBXIP and XIAP suggest that tumours are endowed with resistance against a variety of apoptosis-inducing conditions.

Related Articles

Journal Cover

December 2009
Volume 35 Issue 6

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Krepela E, Dankova P, Moravcikova E, Krepelova A, Prochazka J, Cermak J, Schützner J, Zatloukal P and Benkova K: Increased expression of inhibitor of apoptosis proteins, survivin and XIAP, in non-small cell lung carcinoma. Int J Oncol 35: 1449-1462, 2009.
APA
Krepela, E., Dankova, P., Moravcikova, E., Krepelova, A., Prochazka, J., Cermak, J. ... Benkova, K. (2009). Increased expression of inhibitor of apoptosis proteins, survivin and XIAP, in non-small cell lung carcinoma. International Journal of Oncology, 35, 1449-1462. https://doi.org/10.3892/ijo_00000464
MLA
Krepela, E., Dankova, P., Moravcikova, E., Krepelova, A., Prochazka, J., Cermak, J., Schützner, J., Zatloukal, P., Benkova, K."Increased expression of inhibitor of apoptosis proteins, survivin and XIAP, in non-small cell lung carcinoma". International Journal of Oncology 35.6 (2009): 1449-1462.
Chicago
Krepela, E., Dankova, P., Moravcikova, E., Krepelova, A., Prochazka, J., Cermak, J., Schützner, J., Zatloukal, P., Benkova, K."Increased expression of inhibitor of apoptosis proteins, survivin and XIAP, in non-small cell lung carcinoma". International Journal of Oncology 35, no. 6 (2009): 1449-1462. https://doi.org/10.3892/ijo_00000464